mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels

Cancer Science

Volumn 99, Issue 10, 2008, Pages 1992-2003

  Ghayad, Sandra E ^a,b,c,d   Bieche, Ivan ^c   Vendrell, Julie A ^a,b,c,d   Keime, Celine ^b   Lidereau, Rosette ^c   Dumontet, Charles ^a,b,c   Cohen, Pascale A ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HYDROXYTAMOXIFEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHOSERINE; PROTEIN KINASE B; RAPAMYCIN;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; DNA MICROARRAY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; THERAPY RESISTANCE;

EID: 54949142523     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00955.x     Document Type: Article

References (54)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 2005; 365 (9472): 1727-41.
2. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20 (16): 3386-95.
3. Perey L, Paridaens R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18 (1): 64-9.
4. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3 (4): 371-7.
5. Sun M, Paciga JE, Feldman RI et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001; 61 (16): 5985-91.
6. Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via Tuberin and the small GTPase Ras Homologue Enriched in Brain. Cancer Res 2006; 66 (19): 9461-6.
7. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86 (4): 540-5.
8. Tokunaga E, Kimura Y, Oki E et al. Akt is frequently activated in HER2/ neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006; 118 (2): 284-9.
9. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001; 276 (13): 9817-24.
10. Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 2007; 138 (1): 37-44.
11. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 2006; 13 (3): 863-73.
12. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102 (2): 292-9.
13. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11 (14): 5319-28.
14. deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10 (23): 8059-67.
15. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18 (8): 1323-8.
16. Demirpence E, Duchesne MJ, Badia E, Gagne D, Pons M. MVLN cells: A bioluminescent MCF-7-derived cell line to study the modulation of estrogenic activity. J Steroid Biochem Mol Biol 1993; 46 (3): 355-64.
17. Badia E, Duchesne MJ, Semlali A et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000; 60 (15): 4130-8.
18. Vendrell JA, Magnino F, Danis E et al. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 2004; 32 (2): 397-414.
19. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31 (4): e15.
20. Wu Z, Irizarry RA, Gentleman RC, Martinez Murillo F, Spencer F. A Model Based Background Adjustment for Oligonucleotide Expression Arrays. Baltimore: Johns Hopkins University; 2004.
21. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5 (10): R80.
22. Cohen P, Bouaboula M, Bellis M et al. Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays. J Biol Chem 2000; 275 (15): 11.181-90.
23. Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: A web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics 2004; 20 (4): 578-80.
24. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003; 9 (12): 4415-22.
25. Vendrell JA, Bieche I, Desmetz C et al. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer 2005; 12 (1): 75-92.
26. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182.780 in ERalpha-positive breast cancer cells. Mol Endocrinol 2003; 17 (3): 356-65.
27. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164.384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992; 89 (9): 4037-41.
28. Oldham S, Hafen E. Insulin/IGF and target of rapamycin signaling: A TOR de force in growth control. Trends Cell Biol 2003; 13 (2): 79-85.
29. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26 (13): 1932-1940.
30. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66 (3): 1500-8.
31. Glaros S, Atanaskova N, Zhao C, Skafar DF, Reddy KB. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol Endocrinol 2006; 20 (5): 996-1008.
32. Johnston SR. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int J Gynecol Cancer 2006; 16 (Suppl 2): 543-8.
33. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16 (8): 797-803.
34. Noh WC, Kim YH, Kim MS et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008; 110 (3): 477-483.
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307 (5712): 1098-101.
36. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4 (10): 1533-40.
37. McDonald PC, Oloumi A, Mills J et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008; 68 (6): 1618-24.
38. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273 (23): 14.424-9.
39. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59 (15): 3581-7.
40. Law M, Forrester E, Chytil A et al. Rapamycin disrupts cyclin/ cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 2006; 66 (2): 1070-80.
41. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 2003; 278 (6): 3656-63.
42. Proud CG. Signalling to translation: How signal transduction pathways control the protein synthetic machinery. Biochem J 2007; 403 (2): 217-34.
43. Mayer C, Grummt I. Ribosome biogenesis and cell growth: MTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006; 25 (48): 6384-91.
44. Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 2006; 12 (7 Pt 1): 2080-7.
45. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M. PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence. Breast 2004; 13 (1): 80-1.
46. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24 (11): 1656-64.
47. Jansen MP, Foekens JA, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23 (4): 732-40.
48. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415 (6871): 530-6.
49. Tozlu-Kara S, Roux V, Andrieu C et al. Oligonucleotide microarray analysis of estrogen receptor-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 2007; 39: 305-18.
50. Yamashita S, Masuda Y, Kurizaki T et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007; 27 (4C): 2803-8.
51. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005; 4 (1): 151-68.
52. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12 (4): 721-47.
53. Fan M, Yan PS, Hartman-Frey C et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66 (24): 11.954-66.
54. Chollet P, Abrial C, Tacca O et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7 (4): 336-8.